Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00312286
Recruitment Status : Terminated (Lack of efficacy)
First Posted : April 10, 2006
Last Update Posted : September 23, 2016
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.

Condition or disease Intervention/treatment Phase
Papillomavirus Infections Drug: 851B Phase 2

Detailed Description:

Cervical cancer is caused by infection with specific genotypes of the human papillomavirus referred to as oncogenic or high-risk human papillomavirus. Current epidemiologic evidence suggests that 80% of sexually active women will become infected during their lifetime with human papillomavirus and 50% of these infections will be due to high-risk human papillomavirus. With US annual rates of cervical cancer now in the range of 13,000/year, a very substantial number of women are left with uncertainty regarding whether their infection will clear spontaneously or progress to cancer.

Subjects participating in this study were required to visit the clinic for approximately 15 or 16 visits, and maintain a diary of self-dosing and menstruation cycles. The total time of participation in this study was approximately 27 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 538 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection
Study Start Date : April 2006
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.

Experimental: 2 Drug: 851B
851B 1.5% formulation, gel, topically, twice a week for 1 cycle.

Experimental: 3 Drug: 851B
851B 1.5% formulation, gel, topically, twice a week for 2 cycles.

Experimental: 4 Drug: 851B
851B 3.0% formulation, gel, topically, once a week for 1 cycle.

Experimental: 5 Drug: 851B
851B 3.0% formulation, gel, topically, once a week for 2 cycles.

Experimental: 6 Drug: 851B
851B 3.0% formulation, gel, topically, twice a week for 1 cycle.

Experimental: 7 Drug: 851B
851B 3.0% formulation, gel, topically, twice a week for 2 cycles.

Placebo Comparator: 8 Drug: 851B
851B placebo-matching gel, topically, once a week for 1 cycle.

Placebo Comparator: 9 Drug: 851B
851B placebo-matching gel, topically, twice a week for 1 cycle.

Placebo Comparator: 10 Drug: 851B
851B placebo-matching gel, topically, once a week for 2 cycles.

Placebo Comparator: 11 Drug: 851B
851B placebo-matching gel, topically, twice a week for 2 cycles.




Primary Outcome Measures :
  1. Time to clearance of high-risk human papillomavirus infection. [ Time Frame: At each visit ]

Secondary Outcome Measures :
  1. Proportion of subjects with evidence of regression to normal cytology. [ Time Frame: Screening Visit and Follow-up Visits (Months 6, 8, 14, 20, and 26). ]
  2. Proportion of subjects with improvement in cervical lesions as rated by the investigator (measured by colposcopy). [ Time Frame: At each visit ]
  3. Proportion of subjects who develop histological evidence of cervical intraepithelial neoplasia. [ Time Frame: Visits 1-3 as assigned by group ]
  4. Time to progression of disease to precancer. [ Time Frame: Visits 1-3 as assigned by group ]
  5. Change in relative light units ratios relative to the positive control from Hybrid Capture 2® assay (semi-quantitatively assessing viral load). [ Time Frame: At each visit ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A female subject of childbearing potential who is sexually active using contraception.
  • Subject is willing to abstain from all sexual contact involving her genitalia for at least 24 hours prior to and 24 hours after study drug administration.
  • Subject must be neither pregnant nor lactating from Screening throughout the duration of the study.
  • Subject has 1 of the following:

    • Menstruating with a stable cycle and has at least 21 non-bleeding days.
    • Amenorrheic (due to injectable or extended-cycle contraceptives).
  • Subject is willing to refrain from using vaginal douche products during the treatment period and through the Follow-up Month 4 visit.
  • Subject has a Pap test interpretation of either low-grade squamous intraepithelial lesions or atypical squamous cells of undetermined significance.
  • Subject has a uterine cervical sample that is high-risk human papillomavirus positive.

Exclusion Criteria:

  • The Subject has evidence of an uncontrolled, clinically significant medical condition as determined by the investigator.
  • The Subject has a history of hemorrhagic diatheses or coagulopathy.
  • The Subject has a history of toxic shock syndrome.
  • The Subject has received any of the following medications in the timeframes listed below:

    • 851 (in any form) or an active (non-placebo) human papillomavirus vaccine at any time prior to the screening visit.
    • In the 4 weeks prior to the screening visit the subject has received:

      • Interferon therapy or other therapies that promote a proinflammatory immune state, including:

        • immunomodulators.
        • cytotoxic drugs.
        • drugs known to have major organ toxicity.
      • Used a vaginal douche 72 hours prior to the screening visit.
      • Received any investigational drug within 60 days of Study Day 1.
      • Used in the 2 weeks prior to Study Day 1:

        • oral or inhaled corticosteroids (>1000 mcg/day, fluticasone propionate >600 mg/day, or equivalent).
        • systemic steroids.
        • topical drugs to the anogenital area.
        • NuvaRing.
  • The Subject has a history of hypersensitivity to any components of the gel formulation or to iodine.
  • The Subject has given birth or has had a spontaneous or induced abortion within 2 months of Study Day 1.
  • The Subject uses an intrauterine device, diaphragm, NuvaRing, or additional contraceptive foam or gel for birth control.
  • The Subject has:

    • histology read as high-grade cervical intraepithelial neoplasia.
    • cytology read as high-grade squamous intraepithelial lesion.
    • cytology read as atypical glandular cytological abnormalities.
    • cytology read as atypical squamous cells - cannot exclude high grade.
    • cervical carcinoma of any type.
    • apparent endocervical involvement.
    • high-grade vulvar intraepithelial neoplasia.
    • high-grade vaginal intraepithelial neoplasia.
  • If the limits of a cervical lesion cannot be readily visualized.
  • If the limits of the transformation zone cannot be readily visualized.
  • The subject has clinical evidence of a vaginal infection or sexually transmitted infection, other than cervical human papillomavirus infection at the Study Day 1 visit.
  • The Subject has had a cervical biopsy within 1 month prior to the screening visit.
  • The Subject has had any previous ablative or surgical treatment of the cervix within 3 months prior to the screening visit;
  • The Subject has a history of alcoholism or substance abuse within 1 year or has current alcohol or substance abuse as assessed by the investigator.
  • The Subject has tested positive for human immunodeficiency virus at the screening visit or has evidence of any other immunosuppressive disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00312286


  Show 93 Study Locations
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Medical Director Takeda

Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00312286     History of Changes
Other Study ID Numbers: 1547-851B
U1111-1127-5771 ( Registry Identifier: WHO )
First Posted: April 10, 2006    Key Record Dates
Last Update Posted: September 23, 2016
Last Verified: September 2016

Keywords provided by Takeda:
Cervical Neoplasms
Drug Therapy
Human Papillomavirus
Cervical Human Papillomavirus
Cervical Dysplasia
Chemoprevention
High Risk Cervical Human Papillomavirus
Atypical Squamous Cells of Undetermined Significance
Low Grade Intraepithelial Lesions

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections